Despite increased awareness, evolving knowledge, and therapeutic advances, many patients with type 2 diabetes mellitus (T2DM) fail to meet evidence-based treatment goals. As understandings of the disease have increased, so has the development of newer medications with unique mechanisms of action. With the recent approval of the first agent in the sodium glucose cotransporter 2 (SGLT-2) drug class and others in clinical trials, clinicians need to be aware of the role this novel drug class will play in diabetes management.
Part of the Diabetes Learning Center designed to improve T2DM clinical practice, this roundtable discussion convenes 3 renowned diabetes experts to explore the latest data on the potential benefits and risks of the SGLT-2 inhibitor drug class, and how these agents can best be used to treat T2DM. The faculty will share their unique perspectives on the concept of personalized diabetes medicine, and will discuss how they currently treat their own patients. Accreditor Disclosure of Conflicts of Interest Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. FACULTY DISCLOSURES Silvio Inzucchi, MD (CHAIR),
is a consultant to Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen, and Merck. He is also a speaker for Merck.
Mark E. Molitch, MD,
receives grant/research support from Novartis and Novo Nordisk. He is also a consultant to Bristol-Myers Squibb/AstraZeneca, Eli Lilly, Janssen Therapeutics, Novartis, and Novo Nordisk. John Gerich, MD,
is a consultant to Boehringer-Ingelheim/Lilly, Bristol-Myers Squibb/AstraZeneca, Janssen Therapeutics, and MannKind. He is on the speakers' bureaus of Boehringer-Ingelhiem/Lilly, Bristol-Myers Squibb, Janssen Therapeutics, MannKind, and Merck. Elliot Sternthal, MD,
CME reviewer for Boston University School of Medicine, has no relevant financial relationships or conflicts of interest. *Unlabeled/investigational uses of commercial products is discussed in this activity: Safety/efficacy data for the investigational agent empagliflozin will be presented. STAFF DISCLOSURES
Susan Basilico and Krista Sierra of Haymarket Medical Education, have nothing to disclose with regard to commercial interest.
Michael Burk, Program Manager of Boston University School of Medicine, has no relevant financial relationships or conflicts of interest. ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine (BUSM) and Haymarket Medical Education. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement(s)
Boston University School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™
. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Certificates: MD/Physician and NON-MD Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Boston University School of Medicine Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
This program is sponsored by Boston University School of Medicine.
Supported by an educational grant from Janssen Therapeutics.
Produced by Haymarket Medical Education
If you have any CME questions please email the BUSM Continuing Medical Education department at: email@example.com.